![Jan Beck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Jan Beck is currently the Director at Life Science Washington and a Member at the Association of Washington Business.
He is also the Chief Operating Officer at Mozart Therapeutics, Inc. starting from 2022.
Previously, he worked as the Head-Research & Development Operations at Lyell Immunopharma, Inc.
Actieve functies van Jan Beck
Bedrijven | Functie | Begin |
---|---|---|
Mozart Therapeutics, Inc.
![]() Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Operationeel Directeur | 21-03-2022 |
Life Science Washington | Directeur/Bestuurslid | - |
Association of Washington Business | Corporate Officer/Principal | - |
Eerdere bekende functies van Jan Beck
Bedrijven | Functie | Einde |
---|---|---|
LYELL IMMUNOPHARMA, INC. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
LYELL IMMUNOPHARMA, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Mozart Therapeutics, Inc.
![]() Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Health Technology |
Life Science Washington | |
Association of Washington Business |